Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · NRIX · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
29
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Nurix Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
NRIX insider buying and selling by quarter
NRIX insider selling · NRIX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · NRIX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
NRIX executive sell shares · NRIX board member insider trading · NRIX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 2, 2026 | Ring Christine Chief Legal Officer | Option | 3,422 | $6K | Form 4 |
| Jun 2, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $135K | Form 4 |
| May 5, 2026 | van Houte Hans CFO | Sale | 13,473 | $223K | Form 4 |
| May 5, 2026 | van Houte Hans CFO | Sale | 582 | $10K | Form 4 |
| May 4, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $138K | Form 4 |
| May 1, 2026 | Ring Christine Chief Legal Officer | Sale | 5,394 | $90K | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Option | 2,858 | — | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Sale | 2,388 | $40K | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Option | 3,750 | — | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Option | 2,000 | — | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Option | 2,858 | — | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Option | 3,750 | — | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Sale | 3,214 | $53K | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Option | 2,000 | — | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 2,858 | — | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 3,750 | — | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Sale | 3,214 | $53K | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 2,000 | — | Form 4 |
| Apr 2, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $124K | Form 4 |
| Mar 2, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $126K | Form 4 |
| Feb 9, 2026 | Ring Christine Chief Legal Officer | Sale | 14,261 | $238K | Form 4 |
| Feb 3, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 31,333 | $26K | Form 4 |
| Jan 30, 2026 | van Houte Hans CFO | Option | 2,859 | — | Form 4 |
| Jan 30, 2026 | van Houte Hans CFO | Option | 3,750 | — | Form 4 |
| Jan 30, 2026 | van Houte Hans CFO | Sale | 3,588 | $59K | Form 4 |
Ring Christine
Chief Legal Officer
Date
Jun 2
Shares
8,148
Price
$16.60
Value
$135K
Ring Christine
Chief Legal Officer
Date
May 4
Shares
8,148
Price
$16.96
Value
$138K
Ring Christine
Chief Legal Officer
Date
Apr 30
Shares
3,214
Price
$16.65
Value
$53K
Hansen Gwenn
Chief Scientific Officer
Date
Apr 30
Shares
3,214
Price
$16.65
Value
$53K
Ring Christine
Chief Legal Officer
Date
Apr 2
Shares
8,148
Price
$15.24
Value
$124K
Ring Christine
Chief Legal Officer
Date
Mar 2
Shares
8,148
Price
$15.44
Value
$126K
Ring Christine
Chief Legal Officer
Date
Feb 9
Shares
14,261
Price
$16.66
Value
$238K
Hansen Gwenn
Chief Scientific Officer
Date
Feb 3
Shares
31,333
Price
$0.84
Value
$26K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About NRIX insider trading
NRIX insider trades
Nurix Therapeutics, Inc. (NRIX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Ring Christine (Chief Legal Officer), van Houte Hans (CFO), Hansen Gwenn (Chief Scientific Officer). Over the past 12 months, 3 insiders have filed transactions with the SEC. NRIX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Nurix Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
NRIX insider trading · 5 questionsThe insiders of Nurix Therapeutics, Inc. (NRIX) include executives and directors such as Ring Christine (Chief Legal Officer), van Houte Hans (CFO), Hansen Gwenn (Chief Scientific Officer), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026